重要的是,icSARS-CoV-2除了保留合成工程的标记外并并没有获得其他突变。合成标记是在基因组ORF7中引入报告基因,生成mNeonGreen SARS-CoV-2(ICSARS-CoV-2mNG)。icSARSCoV-2mNG可用于评估干扰素的抗病毒活性。 全长SARS-CoV-2的cDNA感染克隆的合成 本研究的icSARSCoV-2mNG即在ORF7中增加了荧光报告系统,可以通...
针对 SARS-CoV-2 开发的治疗性单克隆抗体也显示出对更具攻击性的VOC（例如奥密克戎BA.5亚变体）的疗效降低。 在当前的研究中，科学家们已将基于细胞的高内涵筛选应用于植物、真菌、细菌和海洋海绵衍生的天然化合物库，以鉴定针对 SARS-CoV-2 的有效抗病毒剂。天然产物筛选 使用mNeonGreen(mNG)报告基因 SARS-Co...
针对SARS-CoV-2 开发的治疗性单克隆抗体也显示出对更具攻击性的VOC(例如奥密克戎BA.5亚变体)的疗效降低。 在当前的研究中,科学家们已将基于细胞的高内涵筛选应用于植物、真菌、细菌和海洋海绵衍生的天然化合物库,以鉴定针对 SARS-CoV-2 的有效抗病毒剂。 天然产物筛选 使用mNeonGreen(mNG)报告基因 SARS-CoV-...
Neutralization titers of human sera were measured by a fluorescent focus reduction neutralization test (FFRNT) using the mNG reporter SARS-CoV-2. Briefly, Vero E6 cells (2.5 × 104) were seeded in each well of black μCLEAR flat-bottom 96-well plate (Greiner Bio-one™). The cells ...
Using a TCID50 (tissue culture infectious dose 50) assay and confocal microscopy, we show the quantification of SARS-CoV-2-mNG signal in proximal tubular cells of the kidney organoids. For complete details on the use and execution of this protocol, please refer to Rahmani etal. (2022)....
提高SARS-CoV-2刺突蛋白(spike, S)的表达水平对于COVID-19疫苗的研发至关重要。之前的研究主要集中在设计受体结合结构域(RBD)和S2亚基,而氨基末端结构域(NTD)由于对其生物物理约束的理解有限而长期被忽视。2022 年11月23日,伊利诺伊大学厄巴纳-香槟分校Nicholas C.Wu团队欧阳文浩、Timothy J.C.Tan等在SCIENCE ADV...
Type I and III interferons (IFN-I/λ) are important antiviral mediators against SARS-CoV-2 infection. Here, we demonstrate that plasmacytoid dendritic cells (pDC) are the predominant IFN-I/λ source following their sensing of SARS-CoV-2-infected cells. Mechanistically, this short-range sensing ...
The COVID-19 pandemic caused by highly-infectious virus namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in infection of millions of individuals and deaths across the world. The need of an hour is to find the innovative solution for diagnosis, prevention, and ...
We used the authentic live SARS-CoV-2 to evaluate neutralization escape. We passaged the SARS-CoV-2-mNG virus in the presence of CoV2-06, CoV2-14, CoV2-06+CoV2-14 for three rounds (Fig.5a). We could recover virus in the presence of individual CoV2-06 or CoV2-14 mAbs but not...
Monoclonal antibodies are a promising approach to treat COVID-19, however the emergence of SARS-CoV-2 variants has challenged the efficacy and future of these therapies. Antibody cocktails are being employed to mitigate these challenges, but neutralizati